In-hospital mortality in patients with lower gastrointestinal bleeding (LGIB) can be significant, depending on various factors. A new tool, the ALIBI score, was developed to predict the risk of death in patients hospitalized with LGIB.
In-hospital mortality in patients with lower gastrointestinal bleeding (LGIB) can be significant, depending on various factors. A new tool, the ALIBI score, was developed to predict the risk of death in patients hospitalized with LGIB. This scoring system helps doctors identify high-risk patients and improve their management.
The ALIBI score is based on five key factors that increase the risk of death: older age, higher Charlson co-morbidity index (indicating more severe underlying health conditions), bleeding that starts during hospitalization, hemodynamic instability (e.g., low blood pressure or shock), and elevated serum creatinine (a marker of kidney function). These factors are combined into a 0–13 point scale.
In a study of 1,198 patients, the ALIBI score was tested and then validated on 752 more patients from multiple countries. It showed strong accuracy in predicting mortality, with higher scores indicating greater risk. Patients were categorized into three risk groups: low risk (0–4 points, 1% mortality), intermediate risk (5–9 points, 4.6% mortality), and high risk (10–13 points, 19.1% mortality).
The ALIBI score outperformed previous tools and can guide doctors in prioritizing care, planning interventions, and improving outcomes for patients with LGIB.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.